生长激素治疗先天性心脏病合并身材矮小患儿初步疗效:6例病例报告并文献复习

Preliminary Efficacy of Growth Hormone Therapy in Children With Congenital HeartDisease and Short Stature: A Six-case Report and Literature Review

  • 摘要: 先天性心脏病(congenital heart disease, CHD)是心脏及大血管胚胎发育异常导致的先天性畸形,占所有先天性畸形的25%左右。CHD患儿常合并身材矮小,虽然手术治疗可在一定程度上改善其生长发育状况,但仍有部分患儿经手术治疗后生长迟缓。重组人生长激素(recombinant human growth hormone,rhGH)是治疗身材矮小的主要药物,但在合并CHD患者治疗中的有效性和安全性仍需进一步研究。本文报道6例应用rhGH治疗CHD合并身材矮小的患儿,并通过文献复习总结和讨论其治疗疗效、随访经验、不良反应等,旨在为临床医生应用rhGH治疗CHD合并身材矮小的患者提供参考和借鉴。

     

    Abstract: Congenital heart disease (CHD) is a congenital malformation resulting from abnormal embryonic development of the heart and great vessels, accounting for approximately 25% of all congenital malformations. Children with CHD are often complicated by short stature. Although surgical treatment can improve their growth and development to a certain extent, some children still experience growth retardation after surgery. Recombinant human growth hormone (rhGH) is the main drug for treating short stature, but its efficacy and safety in the treatment of patients with concomitant CHD warrant further investigation. This article reports six cases of children with CHD and short stature who were treated with rhGH. Through a literature review, we summarize and discuss the therapeutic efficacy, follow-up experiences, and adverse reactions of rhGH treatment, aiming to provide references for clinicians in applying rhGH to treat patients with CHD and short stature.

     

/

返回文章
返回